Expression of CHD1L in bladder cancer and its influence on prognosis and survival

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3687-3690

  Tian, Feng ^a   Xu, Feng ^a   Zhang, Zheng Yu ^a   Ge, Jing Ping ^a   Wei, Zhi Feng ^a   Xu, Xiao Feng ^a   Cheng, Wen ^a  

^a JINLING HOSPITAL   (China)

Author keywords

Bladder cancer; CHD1L; Prognosis

Indexed keywords

PROTEIN CHD1L; TUMOR MARKER; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLADDER CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME;

EID: 84891495253     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0951-4     Document Type: Article

References (16)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29. doi: 10.3322/caac.20138.
2. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol. 2008;180:121-7.
3. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 2011;4:97-113. doi: 10.2147/OTT.S22875.
4. Ma NF, Hu L, Fung JM, Xie D, Zheng BJ, Chen L, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma. Hepatology. 2008;47:503-10. doi: 10.1002/hep.22072.
5. Flaus A, Martin DM, Barton GJ, Owen-Hughes T. Identification of multiple distinct Snf2 subfamilies with conserved structural motifs. Nucleic Acids Res. 2006;34:2887-905. doi: 10.1093/nar/gkl295.
6. Eisen JA, Sweder KS, Hanawalt PC. Evolution of the SNF2 family of proteins: subfamilies with distinct sequences and functions. Nucleic Acids Res. 1995;23:2715-23.
7. Hyeon J, Ahn S, Park CK. CHD1L is a marker for poor prognosis of hepatocellular carcinoma after surgical resection. Korean J Pathol. 2013;47(1):9-15. doi: 10.4132/KoreanJPathol.2013.47.1.9.
8. Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu JL, et al. SPOCK1 is regulated by CHD1L and blocks apoptosis and promotes BC cell invasiveness and metastasis in mice. Gastroenterology. 2013;144:179-91.e4. doi: 10.1053/j.gastro.2012.09. 042.
9. Chen L, Yuan YF, Li Y, Chan TH, Zheng BJ, Huang J, et al. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut. 2011;60:534-43. doi: 10.1136/gut.2010. 224071.
10. Chen L, Chan TH, Yuan YF, Hu L, Huang J, Ma S, et al. CHD1L promotes hepatocellular carcinoma progression and metastasis in mice and is associated with these processes in human patients. J Clin Invest. 2010;120:1178-91. doi: 10.1172/JCI40665.
11. He WP, Zhou J, Cai MY, Xiao XS, Liao YJ, Kung HF, et al. CHD1L protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival. BMC Cancer. 2012;12:437. doi: 10.1186/1471-2407-12-437.
12. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 2005;24:5218-25. doi: 10.1038/sj.onc.1208705.
13. Borden Jr LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2005;17:275-80.
14. Snowdon J, Boag S, Feilotter H, Izard J, Siemens DR. A pilot study of urinary microRNA as a biomarker for urothelial cancer. Can Urol Assoc J. 2012;15:1-5. doi: 10.5489/cuaj.11115.
15. Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol. 2011;21:420-7. doi: 10.1097/MOU.0b013e32834956d6.
16. Wong N, Chan A, Lee SW, Lam E, To KF, Lai PB, et al. Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol. 2003;38:298-306.